Artikel mit Open-Access-Mandaten - Scott RodigWeitere Informationen
Nicht verfügbar: 3
Prüfen
Cytotoxic T cells in PD-L1–positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors
MM Awad, RE Jones, H Liu, PH Lizotte, EV Ivanova, M Kulkarni, ...
Cancer immunology research 4 (12), 1038-1048, 2016
Mandate: Damon Runyon Cancer Research Foundation
Prüfen
Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders
J Xu, HH Sun, CDM Fletcher, JL Hornick, EA Morgan, GJ Freeman, ...
The American Journal of Surgical Pathology 40 (4), 443-453, 2016
Mandate: US National Institutes of Health
Prüfen
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide
AJ Yee, P Hari, R Marcheselli, AK Mahindra, DD Cirstea, TA Scullen, ...
British journal of haematology 166 (3), 401-409, 2014
Mandate: US National Institutes of Health
Verfügbar: 262
Prüfen
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
SM Ansell, AM Lesokhin, I Borrello, A Halwani, EC Scott, M Gutierrez, ...
New England Journal of Medicine 372 (4), 311-319, 2015
Mandate: US National Institutes of Health
Prüfen
An immunogenic personal neoantigen vaccine for patients with melanoma
PA Ott, Z Hu, DB Keskin, SA Shukla, J Sun, DJ Bozym, W Zhang, A Luoma, ...
Nature 547 (7662), 217-221, 2017
Mandate: US National Institutes of Health
Prüfen
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ...
Journal of clinical oncology 27 (26), 4247-4253, 2009
Mandate: US National Institutes of Health
Prüfen
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
B Li, E Severson, JC Pignon, H Zhao, T Li, J Novak, P Jiang, H Shen, ...
Genome biology 17, 1-16, 2016
Mandate: US National Institutes of Health, National Natural Science Foundation of China
Prüfen
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
B Chapuy, C Stewart, AJ Dunford, J Kim, A Kamburov, RA Redd, ...
Nature medicine 24 (5), 679-690, 2018
Mandate: US National Institutes of Health, Bundesministerium für Bildung und Forschung
Prüfen
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
BC Miller, DR Sen, R Al Abosy, K Bi, YV Virkud, MW LaFleur, KB Yates, ...
Nature immunology 20 (3), 326-336, 2019
Mandate: US National Institutes of Health
Prüfen
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ...
Nature communications 7 (1), 10501, 2016
Mandate: US National Institutes of Health, Deutsche Forschungsgemeinschaft, Damon …
Prüfen
Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and …
MR Green, S Monti, SJ Rodig, P Juszczynski, T Currie, E O'Donnell, ...
Blood, The Journal of the American Society of Hematology 116 (17), 3268-3277, 2010
Mandate: US National Institutes of Health
Prüfen
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ...
Cancer discovery 3 (12), 1355-1363, 2013
Mandate: US National Institutes of Health
Prüfen
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
DB Keskin, AJ Anandappa, J Sun, I Tirosh, ND Mathewson, S Li, ...
Nature 565 (7738), 234-239, 2019
Mandate: US National Institutes of Health, Howard Hughes Medical Institute
Prüfen
Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study
AM Lesokhin, SM Ansell, P Armand, EC Scott, A Halwani, M Gutierrez, ...
Journal of clinical oncology 34 (23), 2698-2704, 2016
Mandate: US National Institutes of Health
Prüfen
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ...
The lancet oncology 17 (9), 1283-1294, 2016
Mandate: US National Institutes of Health, National Institute for Health Research, UK …
Prüfen
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
BJ Chen, B Chapuy, J Ouyang, HH Sun, MGM Roemer, ML Xu, H Yu, ...
Clinical cancer research 19 (13), 3462-3473, 2013
Mandate: US National Institutes of Health
Prüfen
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
JE Butrynski, DR D'Adamo, JL Hornick, P Dal Cin, CR Antonescu, ...
New England Journal of Medicine 363 (18), 1727-1733, 2010
Mandate: US National Institutes of Health
Prüfen
Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells
KP Koh, A Yabuuchi, S Rao, Y Huang, K Cunniff, J Nardone, A Laiho, ...
Cell stem cell 8 (2), 200-213, 2011
Mandate: US National Institutes of Health, Howard Hughes Medical Institute
Prüfen
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
SJ Rodig, M Mino-Kenudson, S Dacic, BY Yeap, A Shaw, JA Barletta, ...
Clinical cancer research 15 (16), 5216-5223, 2009
Mandate: US National Institutes of Health
Prüfen
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma
B Chapuy, MR McKeown, CY Lin, S Monti, MGM Roemer, J Qi, PB Rahl, ...
Cancer cell 24 (6), 777-790, 2013
Mandate: US National Institutes of Health, Deutsche Forschungsgemeinschaft
Angaben zur Publikation und Finanzierung werden automatisch von einem Computerprogramm ermittelt